The FDA has granted a new indication for pembrolizumab (Keytruda, Merck) to treat adult and pediatric patients with refractory classic Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy.
The indication was granted based on a study evaluating tumor response rate and durability of response, in which 210 patients with refractory or relapsed cHL demonstrated an overall response rate of 69%, with a complete response rate of 22% and a partial